Humacyte, Inc. (NASDAQ:HUMA) Receives Consensus Recommendation of “Buy” from Analysts

Humacyte, Inc. (NASDAQ:HUMA) has received an average rating of “Buy” from the eight ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $13.71.

A number of research firms have recently commented on HUMA. BTIG Research reiterated a “buy” rating and set a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. HC Wainwright reiterated a “buy” rating and set a $15.00 target price (up from $12.00) on shares of Humacyte in a research report on Friday, December 20th. Benchmark increased their price target on Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, December 23rd. Piper Sandler set a $6.00 price target on Humacyte and gave the company a “neutral” rating in a report on Friday, October 18th. Finally, D. Boral Capital restated a “buy” rating and set a $25.00 price target on shares of Humacyte in a report on Tuesday, January 21st.

Humacyte Stock Performance

NASDAQ HUMA opened at $3.92 on Friday. The company has a market capitalization of $493.37 million, a P/E ratio of -2.93 and a beta of 1.30. Humacyte has a one year low of $2.81 and a one year high of $9.97. The stock has a 50 day moving average price of $4.50 and a 200-day moving average price of $5.32.

Insider Transactions at Humacyte

In other news, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the completion of the sale, the director now directly owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. This trade represents a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Laura E. Niklason sold 261,369 shares of Humacyte stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total value of $1,150,023.60. Following the sale, the chief executive officer now owns 1,730,884 shares of the company’s stock, valued at approximately $7,615,889.60. This trade represents a 13.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,500,000 shares of company stock worth $6,606,799. 11.20% of the stock is currently owned by insiders.

Institutional Trading of Humacyte

Several institutional investors and hedge funds have recently made changes to their positions in HUMA. Bank of Montreal Can bought a new stake in shares of Humacyte in the second quarter valued at about $495,000. AQR Capital Management LLC raised its holdings in shares of Humacyte by 1,018.4% in the second quarter. AQR Capital Management LLC now owns 256,342 shares of the company’s stock valued at $1,230,000 after acquiring an additional 233,422 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Humacyte by 504.3% in the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after acquiring an additional 1,334,641 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Humacyte by 32.5% in the second quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock valued at $168,000 after acquiring an additional 8,557 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Humacyte in the third quarter valued at about $174,000. 44.71% of the stock is currently owned by institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.